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ABSTRACT
We assessed the 5-year results of a high-dose cyclophosphamide, carmustine, and thiotepa (CBT) regimen plus
autologous hematopoietic stem cell transplantation (AHST) as an adjuvant consolidation therapy for high-risk
primary breast cancer patients with >10 positive axillary lymph nodes after primary surgery or >4 positive
axillary lymph nodes after neoadjuvant chemotherapy and surgery. The associations of various potential
prognostic factors with the relapse-free survival (RFS) rate and overall survival (OS) rate were determined.
Between October 1992 and March 2000, 177 eligible patients (median age, 46 years) were given high-dose
CBT followed by AHST. At a median follow-up of 63 months, the acute treatment-related mortality was 4.5%.
Estimated 5-year RFS and OS rates were 62% and 68%, respectively, for all patients. For patients with >10
positive axillary lymph nodes after primary surgery, the 5-year RFS and OS rates were 71% and 70%,
respectively, and for patients with>4 positive axillary lymph nodes after neoadjuvant chemotherapy, the 5-year
RFS and OS rates were 53% and 66%, respectively. In 2-sided log-rank tests, earlier disease stage, a lower
lymph node ratio, and a lower tumor score were associated with a prolonged RFS and OS. In a multivariate
proportional hazards model, disease stage and lymph node ratio remained significant. We concluded that
high-dose CBT with AHST for high-risk primary breast cancer is feasible, with comparable efficacy to other
phase II studies. More than a 50% estimated 5-year survival rate was seen in all high-risk primary breast cancer
patients. In accordance with results from recent randomized studies, we need to continue high-dose chemo-
therapy with AHST for patients with high-risk primary breast cancer in the phase III randomized setting.
© 2004 American Society for Blood and Marrow Transplantation
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3NTRODUCTION
Patients with primary breast cancer—with stage IIIB
isease, inﬂammatory breast cancer, stage II or III dis-
ase with 10 metastatic axillary lymph nodes after pri-
ary surgery, or stage II or III disease with 4 axillaryymph nodes that remain positive for metastatic disease a
94fter preoperative neoadjuvant chemotherapy—have a
ery high risk for disease recurrence. Five-year relapse-
ree survival (RFS) rates after administration of adjuvant
tandard-dose chemotherapy (SDC) are 25% to 50% for
atients with10 metastatic axillary nodes [1-7], 30% to
5% for patients with inﬂammatory breast cancer [8],
nd only 20% for patients with4 axillary lymph nodes
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High-Dose Chemotherapy for Primary Breast Cancer
Bhat remain positive for metastatic disease after preoper-
tive neoadjuvant chemotherapy [9]. In the 1980s, Hry-
iuk and colleagues suggested a linear dose-response
elationship in cases of primary and metastatic breast
ancer treated with cytotoxic agents [10-12]. This con-
ept led to the use of high-dose chemotherapy (HDC)
ith autologous hematopoietic stem cell transplantation
AHST) in the treatment of breast cancer. The belief
hat HDC with AHST would be most effective if given
hen the tumor burden was minimal and before the
evelopment of drug resistance led to the suggestion that
DC should be administered as a consolidation treat-
ent after the completion of adjuvant SDC in patients
ith high-risk primary breast cancer.
In phase II studies of adjuvant HDC with AHST,
he 5-year RFS rate for patients with high-risk breast
ancer was approximately 70% [13-23], a rate that
ompares favorably to the typical 5-year RFS rate of
50% in most studies of SDC. However, these results
ere confounded by patient selection bias and disease-
tage migration resulting from the exclusion of pa-
ients with occult stage IV disease during the extensive
valuation of candidates for transplantation [24].
arge-scale randomized phase III clinical trials were
eeded to determine the exact role of HDC with
HST in high-risk primary breast cancer.
Multiple randomized comparisons of SDC versus
DC plus AHST for high-risk primary breast cancer
ave been conducted. Although most results were re-
orted in preliminary form as abstracts, 6 articles were
ublished in peer-reviewed journals [25-30]. The Scan-
inavian Breast Group reported their randomized trial
esults for 525 patients at high risk for relapse because of
ultiple involved axillary lymph nodes who were given a
ailored 5-ﬂuorouracil, epirubicin, and cyclophospha-
ide (FEC) regimen or a high-dose Solid Tumor Au-
ologous Bone Marrow Program-V regimen [27]. The
-year RFS and overall survival (OS) rates were all better
n the group receiving the tailored regimen than in the
roup receiving HDC, but only the RFS reached statis-
ical signiﬁcance. However, the group receiving the tai-
ored regimen actually received more chemotherapy
han the HDC group.
The Eastern Cooperative Oncology Group re-
ently published the results of a randomized study of
40 patients with 10 involved axillary lymph nodes
ho were given either SDC only (6 cycles of cyclo-
hosphamide, doxorubicin, and 5-ﬂuorouracil) or
DC plus HDC (cyclophosphamide and thiotepa) and
HST [29]. There were no differences in the 6-year
FS and OS rates between the 2 groups; however,
mong the 417 patients who fulﬁlled strict eligibility
riteria, the time to recurrence was longer in the
roup also receiving HDC. This study showed that
DC with AHST might reduce the risk for relapse.
Rodenhuis et al. [25] initially reported in 1998 theesults of a randomized phase II study of FEC admin- o
B & M Tstered to 98 patients with extensive involvement of
evel III axillary lymph nodes, and Schrama et al.
ublished a follow-up report in 2002 [28]. The 2
egimens tested were 4 cycles of FEC or 4 cycles of
EC plus HDC (cyclophosphamide, thiotepa, and
arboplatin). In both reports, no signiﬁcant differ-
nces in RFS or OS rates were reported between the
regimens. However, the sample size of the study
ay have been too small to detect a signiﬁcant differ-
nce in survival. In 2003, Rodenhuis et al. [30] re-
orted their large randomized phase III study of 885
atients with multiple involved axillary lymph nodes
ho were given either 5 cycles of FEC or 4 cycles of
EC plus HDC (cyclophosphamide, thiotepa, and
arboplatin) and AHST. Although there were no dif-
erences in 5-year RFS and OS rates, a subgroup
nalysis showed a signiﬁcant advantage in RFS in
atients with 10 involved axillary lymph nodes who
ere given HDC. The survival beneﬁt was particu-
arly marked in patients with a younger age at trans-
lantation, a lower tumor grade, and HER-2/neu–
egative tumors. This study was the ﬁrst randomized
hase III study that reported in a peer-reviewed form
survival beneﬁt for HDC with AHST in certain
atients with high-risk primary breast cancer.
In 2000, we ﬁrst evaluated patients with stage II or
II breast cancer who had either 10 metastatic axillary
ymph nodes after primary surgery or 4 metastatic
xillary lymph nodes after neoadjuvant chemotherapy
nd surgery [26]. Whereas all other randomized phase
II studies included only high-risk patients with multiple
xillary lymph nodes after primary surgery, we were the
rst group whose study also included high-risk patients
ith 4 metastatic axillary lymph nodes after neoadju-
ant chemotherapy—a group with, apparently, the poor-
st prognosis among patients with high-risk primary
reast cancer. In our study, patients were given 8 cycles
f standard-dose 5-ﬂuorouracil, doxorubicin, and cyclo-
hosphamide (FAC) and were then randomly assigned
o be treated with either 2 cycles of high-dose cyclophos-
hamide, etoposide, and cisplatin (CVP) plus AHST or
bservation only. The 3-year RFS rates for the HDC
nd observation-only groups were 48% and 62%, re-
pectively (P  .35), and the OS rates for the same
roups were 58% and 78%, respectively (P .23). How-
ver, a signiﬁcant percentage of patients (20.5%) did not
ollow the original treatment plan, and the double-CVP
egimen turned out to be nonmyeloablative and was thus
ble to be given without AHST. Since then, we have
eveloped a myeloablative regimen of high-dose cyclo-
hosphamide, carmustine, and thiotepa (CBT), with a
armustine dose (450 mg/m2) that is 25% lower than
hat given in the Solid Tumor Autologous Bone Marrow
rogram-I regimen used in a study by the Cancer and
eukemia Group B (CALGB) [31].
We present here the ﬁnal analysis of the results
btained with this myeloablative high-dose CBT reg-
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7men in 11 phase II trials conducted at our institution.
ur objectives were to characterize the treatment-
elated mortality and efﬁcacy of this regimen; to esti-
ate the RFS and OS rates at 5 years; and to deter-
ine which, if any, patient or disease characteristics
ere associated with RFS and OS.
ATIENTS AND METHODS
atient Selection
A total of 177 patients from 11 phase II clinical
rotocols using the CBT regimen as HDC were in-
luded in this analysis. Each protocol was designed to
ddress a different issue of HDC with AHST in high-
isk primary breast cancer, such as the stem cell source,
he method of peripheral blood progenitor cell (PBPC)
obilization, or the effect of cytokine or growth factor
upport. Eligibility criteria included a histologically con-
rmed diagnosis of invasive carcinoma of the breast with
igh-risk features but no distant metastases. High-risk
eatures included stage II or III disease with 10 meta-
tatic axillary lymph nodes after primary surgery or 4
xillary lymph nodes still positive for metastatic disease
fter preoperative neoadjuvant chemotherapy. Nineteen
atients with fewer than 10 involved lymph nodes after
rimary surgery and 5 patients with fewer than 4 in-
olved lymph nodes after neoadjuvant chemotherapy
ere also given HDC with AHST because of the pres-
nce of other high-risk features, such as positive surgical
argins, vascular invasion, extranodal involvement, a
istologically conﬁrmed grade 3 tumor, or inﬂammatory
ancer. Other eligibility criteria included an age of 60
ears or younger, a Zubrod performance status score of
or 1, and adequate organ function (ie, serum creatinine
oncentration 1.5 mg/dL; total bilirubin and aspartate
nd alanine aminotransferase concentrations 3 times
he normal maximum; a left ventricular ejection fraction
f at least 50%; and a forced expiratory volume in
second and diffusing capacity of carbon monoxide of at
east 50% of predicted values). Tumors that stained
ositively for the estrogen receptor, the progesterone
eceptor, or both were considered hormone-receptor
ositive. The Institutional Review Board of The Uni-
ersity of Texas M.D. Anderson Cancer Center ap-
roved the protocols, and all patients provided written
nformed consent to participate. Patients were entered
nto the studies from October 19, 1992, to March 31,
000.
tem Cell Collection
Either PBPCs or bone marrow cells were collected
or transplantation. PBPCs were collected by using che-
omobilization plus cytokines (112 patients) or cyto-
ines alone (58 patients). The other 7 patients had bone
arrow cells collected in the beginning. The chemomo-
ilization regimen consisted of CVP (cyclophosphamide 8
96500 mg/m2 intravenously [IV] over 24 hours for 3 days
or a total dose of 4500 mg/m2; etoposide 250 mg/m2 IV
or 3 days for a total dose of 750 mg/m2; and cisplatin 40
g/m2 IV daily for 3 days for a total dose of 120 mg/m2).
lso administered for mobilization were mesna 500
g/m2 IV given for 30 minutes before the ﬁrst dose of
yclophosphamide, 2000 mg/m2 given as a continuous
4-hour infusion for 3 days, and granulocyte colony-
timulating factor (G-CSF; ﬁlgrastim) 6 g/kg subcuta-
eously (SC) given twice daily from the fourth day of
hemomobilization until the apheresis was completed.
BPCs were collected during hematopoietic recovery,
fter the white blood cell count was at least 2  109/L.
pheresis was performed daily until a target cell dose of
 106 CD34 cells per kilogram body weight was
ollected. The minimum acceptable cell dose was 2 
06 CD34 cells per kilogram. Three patients were also
iven interleukin-3 during chemomobilization. PBPC
obilization by cytokines alone was accomplished by
iving patients G-CSF 6 g/kg SC twice daily for 4 days
ntil apheresis was completed. Five patients were also
iven an Flt-3 ligand together with the cytokine for
obilization.
PBPCs were not successfully collected by either
hemomobilization or cytokines alone in 17 patients,
o bone marrow cells were obtained instead. A total of
4 patients used bone marrow cells. Bone marrow
ells were collected by multiple aspirations while the
atient was under general anesthesia. At least 2  108
ononuclear cells per kilogram were collected.
BPCs and bone marrow cells were cryopreserved by
rogrammed freezing in 5% dimethyl sulfoxide before
he HDC regimen was begun and were then thawed
nd infused on the day of transplantation.
onditioning Regimen and Supportive Care
The high-dose CBT regimen consisted of cyclo-
hosphamide 2000 mg/m2 IV on days7,6, and5
efore AHST (total dose, 6000 mg/m2); carmustine
50 mg/m2 IV on days 7, 6, and 5 (total dose,
50 mg/m2); and thiotepa 240 mg/m2 IV on days 7,
6, and5 (total dose, 720 mg/m2). Mesna was given
t a dosage of 500 mg/m2 IV 30 minutes before the
rst dose of cyclophosphamide and then at a dosage of
000 mg/m2 as a continuous 24-hour infusion for
days. The autologous PBPCs or bone marrow cells
ere infused on day 0. G-CSF was administered SC
aily from day 1 through the ﬁrst day that the absolute
eutrophil count exceeded 1000/L or for a maxi-
um of 28 days.
Infection prophylaxis consisted of acyclovir, ﬂu-
onazole, and an orally administered quinolone or a
onabsorbable antibiotic drug during the period of
eutropenia. Irradiated blood products were given as
eeded to maintain a hemoglobin level greater than
g/dL and a platelet count greater than 20  109/L.
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High-Dose Chemotherapy for Primary Breast Cancer
Bosttransplantation Evaluation
Toxicity was assessed according to the National
ancer Institute’s common toxicity criteria version 2.0
National Cancer Institute, Bethesda, MD). Disease
valuations to rule out relapse or metastasis were per-
ormed at 3, 6, 9, and 12 months after AHST, with
dditional evaluations as clinically indicated. Evaluations
onsisted of taking a medical history, performing a phys-
cal examination, obtaining a complete blood count and
comprehensive metabolic proﬁle, and determining dis-
ase stage through results of a chest radiograph; a total
ody bone scan; chest, abdominal, and pelvic computed
omographic scans; and tumor marker (carcinoembry-
nic antigen and CA-27.29) measurements.
tatistical Analysis
The study end points included survival time (deﬁned
s the interval from the day of transplantation until death
r the end of the follow-up period) and time to relapse
deﬁned as the interval from the day of transplantation
ntil disease relapse). The event in RFS analysis was
isease relapse, whereas in OS analysis, it was death from
rogressive disease or treatment-related causes. All data
ere updated through August 31, 2003. Survival time
nd time to relapse were estimated by the Kaplan-Meier
roduct-limit method. The 2-sided log-rank test was
sed to test for associations between patient or disease
haracteristics and RFS or OS. Age at transplantation
50 versus 50 years) and other potential prognostic
actors, such as tumor size, hormone receptor status,
isease stage, tumor nuclear grade (grade 3 versus oth-
rs), node ratio (deﬁned as the number of metastatic
xillary nodes divided by the total number of nodes
emoved), number of metastatic axillary nodes, tumor
core (a scoring system developed by Nieto et al. [32]),
nd stem cell type, were used to ﬁt a Cox proportional
azards model with RFS or OS as the outcome variable.
umor size and node ratio were treated as continuous
ariables. Disease stage was grouped into 4 levels (IIA,
IB, IIIA  IIIB [noninﬂammatory], and IIIB [inﬂam-
atory]) and categorized into 3 indicators; stage IIA was
sed as the reference level. A stepwise backward proce-
ure was used to select the ﬁnal model (keeping covari-
tes in the model with P values.10). A P value of.05
as considered statistically signiﬁcant in all analyses.
ESULTS
atient Characteristics and Treatment
Patient characteristics are shown in Table 1. The
edian age of participants was 46 years (range, 22-63
ears). Sixty-two percent of the women were premeno-
ausal, and 26% were postmenopausal. Most patients
69%) had stage IIB or IIIA disease, but 18 (10%) had
tage IIIB inﬂammatory breast cancer; most patients p
B & M T92%) had invasive ductal carcinoma. Seventy-ﬁve per-
ent of the tumors were grade 3, and 55% were 2 to 5
m; 13% were 2 cm, and 32% were 5 cm. Eighty-
wo patients (46%) had locally advanced disease and
nderwent preoperative neoadjuvant chemotherapy.
even-six patients received anthracycline-containing
egimens, and 17 were given taxane-containing regi-
ens. Seventy-seven of these 82 patients had 4 in-
olved lymph nodes after neoadjuvant chemotherapy
nd surgery. Ninety-ﬁve patients (54%) underwent pri-
ary surgery; 76 of them had 10 involved lymph
odes. Hormone receptor status was positive in 126
atients (71%), but only 88 of them (70%) received
osttransplantation hormonal therapy. Also, only 112
able 1. Characteristics of 177 Patients with High-Risk Primary
reast Cancer
Characteristic
No.
Patients
ge at transplantation (y)
Median 46
Range 22-63
enopausal status
Premenopausal 110 (62%)
Postmenopausal 46 (26%)
Unknown 21 (12%)
umor histology
Ductal 163 (92%)
Lobular 11 (6%)
Mucinous 3 (2%)
umor size—clinical (n  136)*
<2 cm 18 (13%)
2-5 cm 75 (55%)
>5 cm 43 (32%)
isease stage
IIA 20 (11%)
IIB 63 (36%)
IIIA 59 (33%)
IIIB, inflammatory 18 (10%)
IIIB, noninflammatory 17 (10%)
umor grade (n  163)*
1 or 2 41 (25%)
3 122 (75%)
ode ratio (n  176)*
<0.8 121 (69%)
>0.8 55 (31%)
ormone receptor (ER and/or PR) status
Negative 51 (29%)
Positive 126 (71%)
reoperative neoadjuvant chemotherapy
Yes 82 (46%)
No 95 (54%)
raft type
Bone marrow 24 (14%)
PBSC 153 (86%)
obilization regimen (n  170)*
CVP plus G-CSF 112 (66%)
G-CSF 58 (34%)
VP indicates cyclophosphamide, etoposide, and cisplatin; ER,
estrogen receptor; PR, progesterone receptor; PBSC, peripheral
blood stem cell.
Information was unknown in some patients.atients (63%) underwent chest wall radiation therapy
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7fter transplantation. Most patients (86%) received a
ransplant of PBPCs instead of bone marrow.
utcome
The median follow-up time was 63 months
range, 19-111 months) after transplantation. Of
he 177 patients in our study, 61 (34%) experienced
isease relapse after receiving the transplant. The
edian time to disease relapse was 1.5 years (range,
.02-1.5 years). The estimated 5-year RFS rate was
2% (95% conﬁdence interval, 55%-71%) for all
atients (Figure 1). Fifty-eight patients (33%) died,
within the ﬁrst 100 days after stem cell transplan-
ation (2 of fungal pneumonia, 1 of cytomegaloviral
neumonia, 1 of Pneumocystis carinii pneumonia, 2
f interstitial pneumonitis, 1 of chronic active hep-
titis-induced hepatic failure, and 1 of unknown
auses). The treatment-related mortality rate was
.5% (8 patients). The estimated 5-year OS rate was
8% (95% conﬁdence interval, 62%-76%) for all
atients (Figure 2).
For patients with 10 positive axillary lymph
odes after primary surgery, the 5-year RFS and OS
ere 71% and 70%, respectively, whereas for pa-
ients with 4 positive axillary lymph nodes after
eoadjuvant chemotherapy, the 5-year RFS and OS
roportions were 53% and 66%, respectively (Fig-
res 3 and 4). No cases of secondary acute myelog-
nous leukemia or myelodysplastic syndrome were
eported among the survivors.
ssociations between Patient Characteristics and
urvival
Patient characteristics, including age at stem cell
ransplantation, tumor size, hormone receptor status,
isease stage, tumor grade, node ratio, number of
etastatic axillary lymph nodes, tumor score, and
tem cell type, were evaluated for possible associations
ith RFS or OS. Results of a 2-sided log-rank test
igure 1. Kaplan-Meier overall relapse-free survival curve (all pa-
ients).howed that age younger than 50 years at transplan- F
98ation, a lower disease stage, a node ratio of less than
.8, a tumor score of less than 2.41, and a stem cell
ype of PBPCs were all associated with a longer RFS
Table 2; Figures 5-7). However, only a lower disease
tage, a node ratio of less than 0.8, and a tumor score
f less than 2.41 were associated with better OS (Ta-
le 2). Node ratio was also evaluated for possible
ssociation with survival in patients given neoadjuvant
hemotherapy, and it was found that a node ratio of
ess than 0.8 was associated with better progression-
ree survival and OS (Table 2).
ultivariate Analysis of Survival
In our multivariate analysis of RFS or OS, patient
ge at transplantation, tumor size, hormone receptor
tatus, disease stage, nuclear grade (grade 3 versus all
thers), node ratio, number of metastatic axillary
odes, tumor score, and stem cell type were used to ﬁt
Cox proportional hazards model, with RFS or OS as
he outcome variable. Results of the stepwise back-
ard procedure used to select the ﬁnal model are
ummarized in Table 3. Node ratio and disease stage
ere signiﬁcantly associated with RFS or OS after
djustment for other factors in the model. Age at
ransplantation and tumor score, although included in
he model, were not signiﬁcant predictors of survival.
ISCUSSION
The CBT HDC regimen has been studied in sev-
ral clinical trials at the M.D. Anderson Cancer Cen-
er over the past 10 years. This analysis shows that
BT HDC produced 5-year RFS and OS rates of
2% and 68%, respectively, whereas our previous
hase II study of 2 cycles of high-dose CVP had an
stimated 3-year RFS and OS of 48% and 58%, re-
pectively [26]. However, a formal comparison be-
ween these 2 studies cannot be made because of the
ifferences in the patient groups. In our present study,igure 2. Kaplan-Meier overall survival curve (all patients).
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High-Dose Chemotherapy for Primary Breast Cancer
Batients had a somewhat more favorable prognosis
ecause a higher percentage (47%) had stage II disease
han in the previous randomized study (29% in the
tandard-dose FAC group and 39% in the standard-
ose FAC plus high-dose CVP group). In addition,
ore patients (71%) in our current study were hor-
one-receptor positive than in the previous study
49% in the standard-dose FAC group and 51% in the
tandard-dose FAC plus high-dose CVP group). Nev-
rtheless, our estimated survival rates were compara-
le to those from other phase II studies. Because the
tudy was the ﬁnal analysis of 11 different protocols,
he patient proﬁles and treatment plans, including
tem cell mobilization, were very heterogeneous.
owever, all of them were given the same HDC of
BT.
Two recently published randomized phase III
tudies have shown a trend toward improved RFS with
DC in cases of high-risk primary breast cancer
29,30]. HDC with AHST in high-risk primary breast
ancer at least seems to have the beneﬁt of reducing
he risk of disease relapse. This survival beneﬁt was
een, however, only in certain subgroups of high-risk
atients, such as patients with a younger age at trans-
lantation. This ﬁnding suggests that HDC with
HST is not for every high-risk patient. Identifying
he patient populations that will beneﬁt most from
his form of treatment has thus become the next major
irection in the study of HDC with AHST as cancer
herapy for high-risk primary breast cancer.
Several studies have attempted to identify the cor-
ect patient subgroups by reporting the prognostic
actors associated with a better survival rate in patients
ith high-risk primary breast cancer who received
DC with AHST. Somlo et al. [33] analyzed the
rognostic factors associated with RFS and OS in 114
atients with high-risk breast cancer who received
DC as adjuvant treatment. In their univariate anal-
igure 3. Kaplan-Meier relapse-free survival curves by preoperative
eoadjuvant chemotherapy.sis, stage IIIB inﬂammatory disease and progester- n
B & M Tne-receptor negativity were predictive of shortened
FS. High tumor grade and hormone-receptor neg-
tivity were associated with decreased OS. The only
igniﬁcant association in their multivariate analysis
as progesterone receptor status. Investigators at the
niversity of Colorado retrospectively reviewed the
ases of 176 patients with high-risk breast cancer who
ad received HDC and found that node ratio, tumor
ize, and hormone receptor status were independent
redictors of clinical outcome [32]. In a follow-up
eport, HER-2/neu status was added to the previous 3
actors as a negative predictor of RFS and OS [34].
Using a 2-sided log-rank test to determine the
ssociation between patient or disease characteristics
nd survival in our current study, we found that 5
actors—a younger age at transplantation, a lower
isease stage, a lower node ratio, a lower tumor score,
nd the use of PBPCs—were associated with longer
FS, but for OS, age and the use of PBPCs were not
ssociated with better outcome as were the other 3
actors. However, in our multivariate analysis, the
nly prognostic factors with statistical signiﬁcance for
FS or OS were node ratio and disease stage; age at
ransplantation, tumor score, and the use of PBPCs
id not emerge as signiﬁcant variables. More surpris-
ngly, the hormone receptor status was not signiﬁ-
antly prognostic of survival rate in either the univar-
ate or the multivariate analysis.
The failure of hormone receptor status to be a
rognostic factor in our study may reﬂect the incon-
istent use of adjuvant endocrine therapy after trans-
lantation. Only 70% of the patients in our study with
ositive hormone receptor status were given adjuvant
ndocrine therapy after stem cell transplantation. One
hird of the patients with positive hormone receptor
tatus did not receive adjuvant endocrine therapy. In
ddition, 37% of patients did not receive posttrans-
lantation radiation therapy. Breast cancer treatment
equires a multidisciplinary approach; the omission of
ny treatment modality—chemotherapy, hormone
igure 4. Kaplan-Meier overall survival curves by preoperative
eoadjuvant chemotherapy.
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8herapy, or radiation therapy—can easily result in a
oorer outcome. Thus, high compliance with the
ultidisciplinary approach is extremely important to
he outcome. Previously, we demonstrated that the
se of maintenance endocrine therapy after HDC
able 2. Estimated 5-Year RFS and OS Rates by Patient Characterist
Characteristic
Total No.
Patients
otal 177
ge at transplantation
<50 y 128
>50 y 49
P value
umor size—pathology (n  158)
<2 cm* 37
2-5 cm 84
>5 cm 37
P value
ormone receptor status
Negative 51
Positive 126
P value
isease stage
IIA* 20
IIB 63
IIIA 59
IIIB, inflammatory 18
IIIB, noninflammatory 17
P value
umor grade (n  163)
1-2 41
3 122
P value
ode ratio (n  176)
<0.8 121
>0.8 55
P value
ode ratio in patients given
neoadjuvant chemotherapy
(n  82)
<0.8 58
>0.8 24
P value
tem cell type
Bone marrow 24
PBPC 153
P value
obilization (n  170)
CVP plus G-CSF 112
G-CSF 58
P value
ositive lymph nodes after
neoadjuvant chemotherapy
<4 5
4-9 38
>10 39
P value
ositive lymph nodes at surgery without neoadjuvant chemother
<10 19
10-19 59
>20 17
P value
VP indicates cyclophosphamide, etoposide, and cisplatin; RFS, re
Reference category.ith AHST improved the progression-free survival in s
00etastatic breast cancer patients with positive hor-
one receptor status [35].
The association of lower disease stage and lower
ode ratio with prolonged RFS or OS was an inter-
sting ﬁnding requiring careful interpretation. In the
No.
Events
No.
Deaths
5-y
RFS
5-y
OS
61 58 62% 68%
39 38 68% 70%
22 20 47% 64%
.01 .11
11 10 70% 73%
28 27 60% 68%
15 12 60% 67%
.59 .70
21 21 55% 7%
40 37 66% 4%
.31 .21
2 2 89% 90%
16 18 69% 72%
25 22 55% 68%
12 11 28% 36%
6 5 65% 69%
<.01 .02
11 12 73% 65%
45 43 59% 72%
.24 .46
35 24 69% 73%
26 34 46% 56%
<.01 .03
23 18 61% 73%
14 13 29% 46%
.01 .01
14 11 43% 62%
47 47 66% 70%
.02 .40
27 42 67% 65%
20 13 66% 76%
.87 .09
1 1 80% 80%
16 12 57% 70%
20 18 45% 61%
.21 .27
2 3 89% 83%
16 17 67% 70%
6 7 63% 56%
.19 .31
ree survival; OS, overall survival.ics
apy
lapse-fetting of metastatic breast cancer, low disease burden
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Bas found to be a predictive factor for chemotherapy
esponse. Therefore, it is reasonable to believe that
iving HDC with AHST to patients with low disease
urden in the adjuvant setting should also have a
etter disease response rate and a longer period of
isease control, which subsequently translate into a
etter survival outcome. However, low disease burden
n general is also associated with better prognosis
egardless of the types of treatment that patients re-
eive. Therefore, without a control group, the ﬁnding
f a lower disease stage and a lower node ratio as
rognostic factors in HDC cannot be concluded
rmly. We must also be cautious in interpreting the
ffect of node ratio in our study because half of our
atients had received neoadjuvant chemotherapy be-
ore primary surgery. The signiﬁcance of node ratio in
uch patients is currently unknown. However, when
he node ratio was evaluated for association with sur-
ival in patients given neoadjuvant chemotherapy, it
lso showed a statistically signiﬁcant correlation (Ta-
le 2). This ﬁnding needs to be veriﬁed in a larger
tudy.
Different risk factors have different weights in
igure 5. Kaplan-Meier relapse-free survival curves by disease stage
t diagnosis.
igure 6. Kaplan-Meier overall survival curves by disease stage of
iagnosis. *
B & M Tffecting outcome. Nieto et al. [32] have developed a
coring system that uses 3 predictive factors—namely,
ode ratio, tumor size, and hormone receptor sta-
us—to determine the risk for relapse after HDC with
HST in patients with high-risk primary breast can-
er. This scoring system has a sensitivity of 60% and
speciﬁcity of 90%; positive and negative predictive
alues are 65% and 88%, respectively. In our study,
he tumor score has shown signiﬁcant correlation with
he survival outcome. One interesting ﬁnding was the
onsistent signiﬁcance of the node ratio, which also
as included in the tumor scoring, in both univariate
nd multivariate analysis. It seemed that the node ratio
as more prognostically signiﬁcant than the absolute
umber of involved lymph nodes.
Although age at transplantation was not a predic-
ive factor in our multivariate analysis, it was associ-
ted with RFS in the 2-sided log-rank test. Younger
Years
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igure 7. Kaplan-Meier relapse-free survival curves by node ratio
number of metastatic axillary nodes divided by the number of
odes removed).
able 3. Summary of Multivariate Proportional Hazards Model
Variable
Hazard Ratio
(95% CI) for RFS
Hazard Ratio
(95% CI) for OS
ge
<50 y*
>50 y 1.59 (0.92-2.66)
P value .10 NS
tage
IIA*
IIB 2.97 (0.68-12.95) 3.15 (0.73-13.57)
P value .15 .12
IIIA  IIIB,
noninflammatory
4.97 (1.19-20.76) 3.97 (0.94-16.73)
P value .03 .06
IIIB, inflammatory 14.19 (3.15-64.06) 8.64 (1.91-39.05)
P value .001 .01
ode ratio
<0.8*
>0.8 3.58 (1.24-10.30) 1.78 (1.05-3.02)
P value .02 .03
I indicates conﬁdence interval; NS, not signiﬁcant.
Reference category.
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8atients usually have better performance status, organ
unction, recovery, and reserves, so they tend to tol-
rate HDC with AHST better than older patients;
owever, breast cancer patients younger than 35 years
ith hormone receptor–positive tumors have a signif-
cantly higher risk for relapse than do older premeno-
ausal patients with such tumors because of the more
ggressive presentation of the disease in younger
omen [36]. Therefore, one could argue that HDC
ith AHST should be the preferred therapy in these
ery young patients with hormone receptor–positive
reast cancer.
Among the high-risk features of primary breast
ancer, having 4 involved lymph nodes after preop-
rative neoadjuvant chemotherapy is particularly as-
ociated with worse RFS. Not many effective thera-
eutic options are available for this subgroup of
atients. Even HDC with AHST is not commonly
erformed in this setting. Our report in 2000 was the
rst and only phase III study that included this group
f high-risk patients [26]. Recently, 2 phase II studies
eported the outcome of HDC with AHST in this
roup of high-risk patients. Palangie et al. [37] re-
orted the use of HDC consisting of thiotepa, mel-
halan, and ifosfamide with AHST in 46 patients with
4 involved lymph nodes after preoperative neoadju-
ant chemotherapy. The treatment-related mortality
as 0%. With a median follow-up of 45 months, the
-year RFS and OS rates were 51% and 68%, respec-
ively. Bou-Khalil et al. [38] reported results with
igh-dose melphalan and thiotepa in 14 patients with
4 involved lymph nodes after preoperative neoadju-
ant chemotherapy. Their treatment-related mortality
as also 0%. After a median follow-up of 26.5 months,
of 14 patients relapsed, and 2 patients died. The
edian time to relapse was 23 months, which is
lightly better than the 18 months usually reported
9,39]. However, the size of the study was too small
nd the follow-up too short to draw a conclusion. Our
urrent study has included the largest number of such
igh-risk patients (82 patients) to date. With a median
ollow-up of 54 months, the 5-year RFS and OS rates
ere 53% and 66%, respectively (Figures 3 and 4),
hich is better than those usually reported (20% and
8%, respectively) [9]. The exact role of HDC with
HST in this group of patients needs to be deter-
ined further in future clinical trials (Figure 8).
In trials of HDC for breast cancer conducted in the
980s, the transplantation-related mortality rate associ-
ted with HDC plus AHST was high (as much as 23%).
he major complications were infections occurring dur-
ng prolonged periods of neutropenia and regimen-re-
ated toxic effects. However, the use of cytokines for
tem cell support, prophylactic antibiotics, and PBPCs as
he source of stem cells have markedly reduced the
ncidence of infections. Regimen-related toxic effects
lso seem to be less severe when hematopoietic recovery w
02ccurs rapidly. Transplantation-related mortality rates
re generally lowest at large centers with experience in
elivering HDC with AHST. Data from the American
lood and Marrow Transplantation Registry show that
s many as 5% of patients with high-risk or metastatic
reast cancer who undergo HDC with AHST die within
00 days of the procedure [16]. In the study reported by
odenhuis et al. [30], the treatment-related mortality
as even less than 1%. In our current study, the mor-
ality rate at day 100 was 4.5%. This could be attribut-
ble to the use of carmustine, which could cause signif-
cant pulmonary toxicity [40]. Most of the deaths (70%)
ere due to either infectious pneumonia or interstitial
neumonitis. In the updated report of the CALGB study
41], which is the only randomized phase III study using
similar carmustine-containing regimen, the treatment-
elated mortality rate in the HDC group was 4% for
atients younger than 40 years but 14% for patients
lder than 50 years. The difference between that study
nd ours could be related to the lower dose of carmustine
n our CBT regimen (450 mg/m2) compared with that in
he CALGB regimen (600 mg/m2).
We conclude that the CBT regimen used in our
tudy as HDC with AHST in patients with high-risk
rimary breast cancer is well tolerated but that the
reatment-related mortality rate needs to be im-
roved. In our study, the 5-year RFS rate was more
han 50% in patients with 10 involved lymph nodes
fter primary surgery or 4 involved lymph nodes
fter neoadjuvant chemotherapy. Most of the survival
as seen in younger high-risk patients with relatively
maller tumor burdens. The signiﬁcance of these ﬁnd-
ngs will need to be further determined. Selection bias
rom eligibility criteria cannot be avoided in trials of
DC with AHST for breast cancer; good perfor-
ance status and major organ function can, by them-
elves, improve survival. Only large randomized trials
igure 8. Kaplan-Meier overall survival curves by node ratio (num-
er of metastatic axillary nodes divided by the number of nodes
emoved).ith sufﬁciently long follow-up will minimize the ef-
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Bect of selection bias on outcome. Recently, 2 large
andomized trials [29,30] both clearly revealed a ben-
ﬁt from HDC with AHST in delaying disease relapse
n the subgroup analysis. This beneﬁt will need to be
urther conﬁrmed in ongoing randomized trials. For
ow, HDC with AHST in patients with high-risk
rimary breast cancer has to be conﬁned to clinical
rials. Directions for future research on HDC with
HST should include the proper selection of patient
roups to receive this kind of treatment and the im-
ortance of posttransplantation maintenance therapy,
uch as hormone therapy in hormone receptor–posi-
ive tumors or trastuzumab in HER-2/neu–positive
umors.
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